Initial infection variable | Outpatients (n = 23) |
---|---|
Age (yrs), median (IQR) | 61.0 (19.0) |
Male sex, no. (%) | 13 (56.5) |
Diagnostic test: PCR, serology, no. (%) | 23 (100.0) |
Vaccination status at infection, no. (%) | 2 (8.7) |
Hospitalization, no. (%) | Â |
 Ward | 7 (30.4) |
 ICU | 1 (4.3) |
Comorbidities, no. (%) | Â |
 Diabetes | 6 (26.1) |
 Hypertension | 8 (34.8) |
 Coronary artery/heart disease | 2 (8.7) |
 Chronic/congestive heart failure | 0 (0.0) |
 Chronic kidney disease | 0 (0.0) |
 Cancer | 1 (4.3) |
 COPD | 0 (0.0) |
 Asthma | 4 (17.4) |
Presenting symptoms at infection, no. (%) | Â |
 Fever | 16 (69.6) |
 Cough | 18 (78.3) |
 Anosmia/ageusia | 14 (60.9) |
 Pharyngitis | 9 (39.1) |
 Headache | 14 (60.9) |
 Confusion/memory | 2 (8.7) |
 Myalgias | 13 (56.5) |
 Dyspnea | 16 (69.6) |
 Chest pain | 8 (34.8) |
 Nausea/vomiting/diarrhea | 12 (52.2) |
Interventions at infection, no. (%) | Â |
 Steroids | 7 (30.4) |
 Remdesivir | 1 (4.3) |
 Tocilizumab | 1 (4.3) |
Long-COVID clinic variables | Â |
 Follow up, days from infection onset, median (IQR) | 98.5 (47.5) |
Lingering symptoms at follow up, no. (%) | Â |
 Respiratory | 16 (69.6) |
 Cardiovascular | 6 (26.1) |
 Neurology | 9 (39.1) |
 Musculoskeletal | 1 (4.3) |
 Gastro-Intestinal | 3 (13.0) |
 Psychiatric | 1 (4.3) |
 Cutaneous | 0 (0.0) |
 Balance | 0 (0.0) |
 Chest pain | 4 (17.4) |
 Concentration | 1 (4.3) |
 Cough | 2 (8.7) |
 Dyspnea | 16 (69.6) |
 Fatigue | 11 (47.8) |
 Headache | 2 (8.7) |
 Low mood | 1 (4.3) |
 Anxiety | 1 (4.3) |
 Memory | 7 (30.4) |
 Nausea | 1 (4.3) |
 Palpitations | 1 (4.3) |
 Paresthesia |  1 (4.3) |
 Smell/taste | 2 (8.7) |
 Word finding | 2 (8.7) |
 Non-specific | 11 (47.8) |
Laboratories at follow up, median (IQR) | Â |
 White blood cell count | 7.1 (2.0) |
 Neutrophils | 4.5 (1.6) |
 Lymphocytes | 2.0 (0.6) |
 Hemoglobin | 140.0 (22.5) |
 Platelets | 230.0 (59.5) |
 C-Reactive Protein (CRP) | 1.8 (3.5) |
 Ferritin | 86.5 (133.8) |
 Lactate dehydrogenase (LDH) | 201.0 (37.0) |
 Alanine aminotransferase (ALT) | 20.0 (10.5) |
Interventions at follow up, no. (%) | Â |
 Pulmicort | 1 (4.3) |
 Anticoagulant | 1 (4.3) |
 Symbicort | 10 (43.5) |
 Ventolin | 3 (13.0) |
 Lasix | 1 (4.3) |
 Nasal spray | 2 (8.7) |
 Oxygen | 2 (8.7) |
 Physiotherapy | 5 (21.7) |
 None | 8 (34.8) |